Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FRINGE

Financiado

Cerrado

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic...

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limite... ver más

31/10/2024

Innovasjon Norge

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 7 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-10-31

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinki...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

Innovasjon Norge

1.15M€ | Lider

VSCHT

382.50K€ | Participante

HIOF

518.63K€ | Participante

"NCSR ""D"""

513.44K€ | Participante

Proyectos interesantes

NuCapCure

Medical Technol...

Applied Physics

6M€ Cerrado

MEDICIS-PROMED

Medical Technol...

Applied Physics

3M€ Cerrado

TRACENTREAT

Medical Technol...

Applied Physics

2M€ Cerrado

Photochem-RS-RP

Medical Technol...

Applied Physics

231K€ Cerrado

RADIANCE

Medical Technol...

Nanotechnology

2M€ Cerrado

CTQ2009-08810

Medical Technol...

Applied Physics

61K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 70 meses Fecha Inicio: 2018-12-18
Fecha Fin: 2024-10-31

Líder del proyecto

Innovasjon Norge No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Deep lying tumours like aggressive brain cancer remain very difficult to treat and existing therapies offer only marginal increase in survival rates. In the case of photomedical therapies they are very effective, but mainly limited by their insufficient depth of light penetration into tissue. Current neutron-based therapies have sufficient penetration depth but suffer from lack of cancer specificity. In FRINGE we propose a genuinely new hybrid-technology. At its heart are chemical agents (photosensitisers - PS) which preferentially accumulate in the tumours especially in brain cancers where the blood brain barrier is compromised. The PSs designed for FRINGE will contain metal centres like Gadolinium (Gd), to enable interaction with incoming neutrons and facilitate the transfer of neutron energy into electron excitation of the PS, confirmed by concomitant fluorescence emission. Interaction with ambient oxygen will generate reactive oxygen species which will kill the tumour cells. The main scientific breakthrough of this project will be to establish experimental proof-of-principle of this novel neutron-activated therapy. FRINGE will combine the advantages of photomedical therapies (no mutagenic radiation) with the advantages of neutron-based therapies (large penetration depth). The externally-applied neutron beam can be energy-tuned to become therapeutic exactly at the depth of the tumour. Exploiting Gd as a contrast agent, FRINGE can also become a theranostic modality by use of magnetic resonance imaging. FRINGE has the potential of causing immunogenic cell death to cancers which could eliminate occult metastasis and act as a ‘cancer vaccine’. The highly interdisciplinary project team comprises world renowned experts from a unique combination of disciplines: Nuclear physicists, synthetic chemists, photochemists, photobiologists, medical physicists, quantum chemists and radio-oncologists will join forces to lay the foundations for a novel, curative cancer therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores